AstraZeneca acquired preclinical biotech Omniose, adding a bioconjugation platform for conjugate vaccines against serious bacterial infections.
|Articles|October 15, 2018
- BioPharm International-10-15-2018
- Volume 2018 eBook
- Issue 3
Glycan Analysis Best Practices
Author(s)Susan Haigney
Experts discuss best practices for performing glycan analysis.
Advertisement
BioPharm International spoke with Aled Jones, senior product and applications manager at ProZyme; Philip Widdowson, European application development scientist at Thermo Fisher Scientific; and Dr Daryl Fernandes, chief executive at Ludger Ltd, about best practices for performing glycan analysis.
Read
Article Details
BioPharm International
eBook: Biopharma Laboratory Best Practices 2018
Vol. 31
October 2018
Pages: 12, 14, 16–17
Citation
When referring to this article, please cite it as S. Haigney, "Glycan Analysis Best Practices," BioPharm International Biopharma Laboratory Best Practices eBook (October 2018).
Articles in this issue
about 8 years ago
An Analytical Approach to Biosimilar Drug Developmentabout 8 years ago
Analytical Best Practices for Raw Materials Testingabout 8 years ago
Best Practices in Analytical Method Development and Testingabout 8 years ago
Complex Protein Studies Demand Dynamic TechniquesAdvertisement
Related to this article
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
Merck's GLP-1/glucagon co-agonist raised MASH resolution versus placebo at 52 weeks, but fibrosis and dose-response questions remain.
Larimar Therapeutics has completed its rolling BLA for nomlabofusp, a frataxin replacement fusion protein, seeking accelerated approval based on skin frataxin as a novel surrogate endpoint. The company expects a potential US approval in mid-2027.
FDA granted RMAT and Fast Track designations to AbelZeta’s anti-CD20/CD19 CAR-T therapy prizlon-cel for relapsed or refractory large B-cell lymphoma. The company plans US studies after prior CAR-T therapy and in the second-line setting.
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
More monoclonal antibodies are moving from IV infusion to subcutaneous injection, but dose, volume, and viscosity still limit the switch. This FAQ covers the formulation science, the enabling technologies, what regulators require, and what remains unresolved.
Advertisement
Advertisement
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
argenx Agrees to Buy Unnatural Products in Up to $1.15 Billion Deal
3
J&J’s Dual-Antigen Bispecific Regimen Achieves 73% PSA Response in Advanced Prostate Cancer
4
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
5